Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Oncologic Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Human IL1A Recombinant Protein (Pro-form & Mature). High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 Expressed. | View IL1A Products |
| Gene Delivery | IL1A Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and alarmin secretion studies. | View IL1A Products |
| Benchmark Ab | Anti-IL1A (Bermekimab Sequence Reference). Recombinant neutralizing control. Sequence Verified. | View IL1A Products |
| Validator | IL1A siRNA Set. For knockdown and specificity verification. | View IL1A Products |
| Related Target: IL1B | IL-1 beta (IL1B). Synergistic IL-1 family cytokine; essential for counter-screening and bispecific development. | View IL1B Products |
| Related Target: IL1R1 | IL-1 Receptor Type 1 (IL1R1). Primary signaling receptor; required for target engagement and reporter assays. | View IL1R1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cyno/Mouse Ortholog Preclinical Evaluation | Human/Mouse/Cynomolgus IL1A proteins available, >95% purity, Sequence Verified |
| IL-1 beta Subfamily Selectivity (Avoid Off-target Neutralization) | IL1B & IL1RN homolog panel proteins strictly verified by mass spec for cross-reactivity screens |
| Lack of Positive Control in Neutralization Assays | Clinical Benchmark Anti-IL1A recombinant antibody (Bermekimab reference sequence) |
| False Positives in Cellular Assays | IL1A-specific siRNA included for target-specificity verification |
Live R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL1A therapeutics is intensifying, with major players shifting focus from broad IL-1 pathway blockade to selective IL-1 alpha neutralization. As first-generation anti-IL1A antibodies advance in oncology and dermatology (e.g., Bermekimab in Hidradenitis Suppurativa, colorectal cancer cachexia), the next wave of R&D is targeting dual-pathway inhibition (IL-1α/β bispecifics), localized delivery for dermatological conditions, and synergistic combinations with immune checkpoint inhibitors. The field is also witnessing emerging small molecule approaches targeting the IL-1 pathway for autoimmune indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Anti-IL1A) | XBiotech, Janssen | Hidradenitis Suppurativa, Colorectal Cancer Cachexia, Oncology | Neutralization Assay (Need high-purity IL1A pro-form & mature protein) |
| Bispecific (Anti-IL1A/IL1B) | AbbVie (ABT-981), Various Biotechs | Osteoarthritis, Inflammatory Diseases, Refractory Inflammation | Heterodimer Validation & Selectivity Panel (Need IL1A/IL1B/IL1RN cross-reactive protein set) |
| Small Molecule | Emerging Innovators | Dermatology, Autoimmune | Receptor Binding Interference (Need High-Purity Antigens) |
| Recombinant Decoy / Antagonist | Preclinical / Academic | Autoimmune Inflammation | Receptor Competition Assay (Need IL1R1 & IL1A co-expression systems) |